Join to view full profile
12901 Bruce B Downs BlvdTampa, FL 33612
Phone+1 813-844-4455
Fax+1 813-844-4456
Dr. Hauser is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Robert Hauser is Director of the Parkinson's Disease and Movement Disorders Center of the University of South Florida. He received his medical degree from Temple University School of Medicine and has been in practice 31 years. He specializes in Parkinson's disease and is an expert in clinical research to develop new treatments for Parkinson's disease and related disorders. He also performs Botox injections for cervical dystonia, blepharospasm, and hemifacial spasm. He has published over 300 peer reviewed articles and lectures frequently at scientific meetings.
Education & Training
Eastern Virginia Medical SchoolResidency, Neurology, 1983 - 1988
Albert Einstein Medical CenterInternship, Transitional Year, 1982 - 1983
Lewis Katz School of Medicine at Temple UniversityClass of 1982
Certifications & Licensure
FL State Medical License 1989 - 2028
CA State Medical License 1986 - 1992
MI State Medical License 1988 - 1990
PA State Medical License 1988 - 1990
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly
- CMS Meaningful Use Stage 1 Certification Outgoing Public Health Reporting from EpicCare Functionality, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- 2 citationsTavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.Hubert H Fernandez, Stuart H Isaacson, Robert A Hauser, Pinky Agarwal, William Ondo
JAMA Neurology. 2026-05-01 - 2 citationsLRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.Anthony E Lang, Robert A Hauser, Lorraine V Kalia, Bonnie Hersh, Zdenek Berger
Movement Disorders. 2026-02-01 - 2 citationsVMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review.Amita R Patel, Robert A Hauser, Leslie Citrome, Laxman Bahroo, Tracy Hicks
CNS Spectrums. 2025-10-22
Journal Articles
- Therapeutic Strategies for Parkinson Disease: Beyond Dopaminergic DrugsRobert Hauser, MD, Nature
- Deutetrabenazine for Treatment of Involuntary Movements in Patients with Tardive Dyskinesia (AIM-TD): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 TrialHubert H Fernandez, Robert A Hauser, The Lancet
Press Mentions
FDA OKs Novel Levodopa-Based Continuous Sub-Q Regimen for Parkinson’s DiseaseOctober 22nd, 2024- Injectable Drug to Ease Advanced Parkinson's Disease Symptoms Approved by FDAOctober 17th, 2024
- FDA Approves New Parkinson’s Treatment Based on Clinical Trial Led by USF Health FacultyAugust 8th, 2024
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
